Effects of combination lipid therapy on @entity3979 progression and clinical cardiovascular events in coronary disease XXXX with @entity209 : a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS).

@entity1 @entity64 @entity583 @entity63 @entity3979 @entity209 @entity453 @entity850 @entity65 @entity165
We examined the impact of @entity209 ( @entity209 ) on @entity65 (CV) events and investigated the mitigating effects of low-density lipoprotein (LDL) @entity165 lowering and LDL @entity165 lowering plus high-density lipoprotein (HDL) @entity165 increasing. This analysis combined individual @entity1 data from 445 subjects who participated in 3 double-blinded, randomized, placebo-controlled trials (FATS, HATS, and AFREGS) comparing intensive lipid therapy to placebos on @entity3979 progression by quantitative coronary angiography and on major CV events. The primary end points were change in mean proximal coronary diameter @entity850 (Delta%S(prox)) over 3 years and the frequency of the predefined composite of @entity453 death, nonfatal @entity583 , @entity64 , and revascularization due to worsening @entity63 . @entity1 with @entity209 had 50% more rapid @entity3979 progression and 64% increased CV event frequency compared to those without. More rapid @entity3979 progression was significantly and independently associated with a 3.5-fold increased event risk (p <0.001). Combination lipid therapy significantly decreased @entity850 progression by 83% (Delta%S(prox) 0.5 vs 2.9, p <0.001) in @entity1 with @entity209 and induced a small net regression in those without (Delta%S(prox) -0.3 vs 2.0, p <0.001). Combination therapy decreased the event rate by 54% (13% vs 28%, p = 0.03) in those with @entity209 and by 82% (3% vs 17%, p = 0.002) without. On average, each 10% decrease in LDL @entity165 or 10% increase in HDL @entity165 was significantly associated with a 0.3 Delta%S(prox) decrease. Each 10% decrease in LDL @entity165 or 10% increase in HDL @entity165 was associated with 11% (p = 0.02) or 22% (p <0.001) event risk decrease. In conclusion, @entity1 with @entity209 have significantly more rapid @entity3979 progression and a higher frequency of CV events. Greater @entity850 progression rate is associated with a higher event rate. LDL @entity165 -lowering and HDL @entity165 -increasing therapies independently and significantly decrease @entity3979 progression and decrease CV events.
